INT20348

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1982
Last Reported 2010
Negated 1
Speculated 0
Reported most in Abstract
Documents 47
Total Number 47
Disease Relevance 19.88
Pain Relevance 7.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Tbxa2r) plasma membrane (Tbxa2r) signal transducer activity (Tbxa2r)
Anatomy Link Frequency
platelet 13
monocytes 3
plasma 2
coronary artery 1
plaque 1
Tbxa2r (Mus musculus)
Pain Link Frequency Relevance Heat
cINOD 48 99.94 Very High Very High Very High
antagonist 31 99.60 Very High Very High Very High
Inflammatory mediators 1 99.48 Very High Very High Very High
cva 69 99.44 Very High Very High Very High
Arthritis 3 99.42 Very High Very High Very High
Inflammation 93 99.00 Very High Very High Very High
aspirin 461 98.96 Very High Very High Very High
Dismenorea 6 98.72 Very High Very High Very High
Serotonin 15 98.64 Very High Very High Very High
COX-2 inhibitor 4 98.50 Very High Very High Very High
Disease Link Frequency Relevance Heat
Increased Venous Pressure Under Development 38 100.00 Very High Very High Very High
Cv General 2 Under Development 8 100.00 Very High Very High Very High
Coronary Heart Disease 9 99.96 Very High Very High Very High
Myocardial Infarction 87 99.92 Very High Very High Very High
Targeted Disruption 5 99.76 Very High Very High Very High
Hypertension 24 99.70 Very High Very High Very High
INFLAMMATION 125 99.66 Very High Very High Very High
Injury 12 99.56 Very High Very High Very High
Cv General 3 Under Development 109 99.44 Very High Very High Very High
Arthritis 3 99.42 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We also compared the effects of picotamide (1200 mg/day), a TxA2-synthase inhibitor and TxA2-receptor antagonist, with those of aspirin (325 mg/day) on myocardial ischemia and TxA2 formation by monocytes and platelets.
Negative_regulation (inhibitor) of TxA2-synthase in platelets
1) Confidence 0.59 Published 1994 Journal Coron. Artery Dis. Section Body Doc Link 8180744 Disease Relevance 0.08 Pain Relevance 0
In volunteers, single-dose studies have demonstrated inhibition of thromboxane A2 (TXA2) formation, with some small increases in bleeding time but no marked effect on platelet aggregation.
Negative_regulation (inhibition) of TXA2 in platelet associated with hemorrhage
2) Confidence 0.56 Published 1990 Journal Circulation Section Abstract Doc Link 2136820 Disease Relevance 0.97 Pain Relevance 0.33
TXRBs rely for their efficacy only on blockade of the TXA2 receptor and antagonize the deleterious effects of both TXA2 and prostaglandin H2 equally, so they represent a simpler pharmacological approach than TXSIs.
Negative_regulation (blockade) of TXA2
3) Confidence 0.56 Published 1990 Journal Circulation Section Abstract Doc Link 2136820 Disease Relevance 0.71 Pain Relevance 0.28
Specific inhibition of the TP receptor may provide a more precise approach to limit inflammation without some of the untoward effects associated with NSAIDs.
Negative_regulation (inhibition) of TP receptor associated with inflammation and cinod
4) Confidence 0.51 Published 2003 Journal J. Immunol. Section Abstract Doc Link 14662837 Disease Relevance 0.92 Pain Relevance 0.40
We also examined the effect of OKY-1581 (8 mg/kg, i.v.), a TXA2 synthetase inhibitor, on the coronary arterial spasticity of these patients.
Negative_regulation (inhibitor) of TXA2 associated with spasticity
5) Confidence 0.50 Published 1987 Journal Jpn. Circ. J. Section Abstract Doc Link 3626009 Disease Relevance 0.94 Pain Relevance 0.43
This interplay may help explain the adverse cardiovascular effects associated with selective COX-2 inhibitors, which, unlike aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), inhibit PGI2 but not TxA2.
Negative_regulation (inhibit) of TxA2 associated with aspirin, inflammation, cinod and cox-2 inhibitor
6) Confidence 0.49 Published 2002 Journal Science Section Abstract Doc Link 11964481 Disease Relevance 0.26 Pain Relevance 0.41
We also compared the effects of picotamide (1200 mg/day), a TxA2-synthase inhibitor and TxA2-receptor antagonist, with those of aspirin (325 mg/day) on myocardial ischemia and TxA2 formation by monocytes and platelets.
Negative_regulation (inhibitor) of TxA2-receptor in platelets
7) Confidence 0.43 Published 1994 Journal Coron. Artery Dis. Section Body Doc Link 8180744 Disease Relevance 0.08 Pain Relevance 0
We also compared the effects of picotamide (1200 mg/day), a TxA2-synthase inhibitor and TxA2-receptor antagonist, with those of aspirin (325 mg/day) on myocardial ischemia and TxA2 formation by monocytes and platelets.
Negative_regulation (antagonist) of TxA2-receptor in platelets
8) Confidence 0.43 Published 1994 Journal Coron. Artery Dis. Section Body Doc Link 8180744 Disease Relevance 0.08 Pain Relevance 0
Recent developments in measurement techniques and the availability of both selective inhibitors of Tx synthetase and TxA2 receptor antagonists have facilitated the implication of TxA2 as a physiological modulator and as a mediator in thrombotic, vasospastic, and bronchospastic conditions.
Negative_regulation (inhibitors) of TxA2 associated with antagonist
9) Confidence 0.43 Published 1987 Journal Fed. Proc. Section Abstract Doc Link 2948837 Disease Relevance 0.22 Pain Relevance 0.12
To address this question, we explored the influences of OKY-046 (a TxA2 synthase inhibitor) and S-1452 (a TP receptor antagonist) on eosinophilic inflammation of the airways using a murine model.
Negative_regulation (inhibitor) of TxA2 associated with rhinitis, inflammation and antagonist
10) Confidence 0.42 Published 1998 Journal Eur. Respir. J. Section Abstract Doc Link 9596113 Disease Relevance 0.62 Pain Relevance 0.23
In volunteers, single-dose studies have demonstrated inhibition of thromboxane A2 (TXA2) formation, with some small increases in bleeding time but no marked effect on platelet aggregation.
Negative_regulation (inhibition) of thromboxane A2 in platelet associated with hemorrhage
11) Confidence 0.41 Published 1990 Journal Circulation Section Abstract Doc Link 2136820 Disease Relevance 0.96 Pain Relevance 0.33
In conclusion, intracoronary administration of a TXA2 synthase inhibitor can relieve ACh-induced coronary spasms by inhibiting TXA2 synthesis in the local coronary circulation.
Negative_regulation (inhibitor) of TXA2 associated with cva
12) Confidence 0.39 Published 2002 Journal Circ. J. Section Abstract Doc Link 12224820 Disease Relevance 0.87 Pain Relevance 0.35
Within 2 min of the administration of the TXA2 synthase inhibitor, ACh-induced coronary spasms were relieved (TIMI 3 flow) in 88.1% of procedures without complications.
Negative_regulation (inhibitor) of TXA2 associated with cva
13) Confidence 0.39 Published 2002 Journal Circ. J. Section Abstract Doc Link 12224820 Disease Relevance 0.97 Pain Relevance 0.35
TXA2 synthetase inhibitors decreased plasma levels of TXB2 in these patients accompanied by attenuation of infarct size.
Negative_regulation (inhibitors) of TXA2 in plasma
14) Confidence 0.33 Published 1988 Journal J. Mol. Cell. Cardiol. Section Abstract Doc Link 3137347 Disease Relevance 0.43 Pain Relevance 0.21
Modulation of hemostasis includes the release of plasminogen activator, tissue factor inhibitor, von Willebrand factor, NO, prostacyclin, TXA2, plasminogen-activator inhibitor-1 (PAI-1), and fibrinogen.
Negative_regulation (inhibitor) of TXA2
15) Confidence 0.32 Published 2005 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993938 Disease Relevance 0.89 Pain Relevance 0.12
HR was almost unchanged by both PG I2 and TXA2 synthetase inhibitor.
Negative_regulation (inhibitor) of TXA2
16) Confidence 0.31 Published 1983 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 6339650 Disease Relevance 0 Pain Relevance 0.08
The possibility of treatment of pregnancy-induced hypertension with PG I2 or TXA2 synthetase inhibitor is discussed.
Negative_regulation (inhibitor) of TXA2 associated with hypertension
17) Confidence 0.31 Published 1983 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 6339650 Disease Relevance 0.10 Pain Relevance 0.10
PG I2 and TXA2 synthetase inhibitor did not induce any increase in intrauterine pressure (IUP).
Negative_regulation (inhibitor) of TXA2 associated with dismenorea
18) Confidence 0.31 Published 1983 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 6339650 Disease Relevance 0.10 Pain Relevance 0.10
PG I2 caused a dose-dependent decrease in UBF, while TXA2 synthetase inhibitor was followed by an insignificant decrease in UBF.
Negative_regulation (inhibitor) of TXA2
19) Confidence 0.31 Published 1983 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 6339650 Disease Relevance 0 Pain Relevance 0.09
PG I2 and TXA2 synthetase inhibitor produced increases in CO and RBF in a dose-dependent manner.
Negative_regulation (inhibitor) of TXA2
20) Confidence 0.31 Published 1983 Journal Nippon Sanka Fujinka Gakkai Zasshi Section Abstract Doc Link 6339650 Disease Relevance 0 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox